Received “Pass” from two tech evaluation agencies… Target to file preliminary review application to KOSDAQExpanding global new drug development platform through IPO. Accelerating innovation for new drug development and business development(For more information, please refer to the link below)https://www.hankyung.com/it/article/201912276015i
pH Pharma signed a collaboration and licensing agreement for ADC development with Venn Therapeutics
pH Pharma, biotech, announced that collaboration and licensing agreement for ADC development made with Immunome, U.S. biotech (For more information, please refer to the link below)http://www.biospectator.com/view/news_view.php?varAtcId=9127
Report on merger termination
download download
New stock issuance notice (common stock)
download download
New stock issuance notice
download download
Announcement of submission of objections to creditors following merger and submission of stock certificates
download download
New stock issuance notice
download download
pH Pharma signed a collaboration and licensing agreement for ADC development with Immunome
pH Pharma, biotech, announced that collaboration and licensing agreement for ADC development made with Immunome, U.S. biotech (For more information, please refer to the link below)http://m.mtn.co.kr/news/news_view.php?id=2019101715184816599
“We has great potential for new drug development” Hoyoung Huh, CEO of pH Pharma, aiming for a special listing onto KOSDAQ
Hoyoung Huh, CEO of pH Pharma, which is targeting to go IPO onto KOSDAQ through special listing for tech company, gave the keynote speech at the Biomedical Innovation Summit held in Madrid, Spain.(For more information, please refer to the link below)http://news.mt.co.kr/mtview.php?no=2019071514344805346
New stock issuance notice
On May 28, 2019, the same contents as attached will be announced (notified) by a resolution of the board of directors. download download